AphioTx is excited to announce we have been chosen to advance to the top 10 at Start Up TNT’s Life Sciences Investment Summit. Watch the recording of our pitch that landed us the next spot in the summit.
Over a 15-year period, key scientific discoveries were made that changed our understanding of the important roles pannexin-1 channels play in opioid withdrawal, chronic pain, stroke, and cognitive impairment. These discoveries were led by three researchers from the Hotchkiss Brain Institute at the University of Calgary: Drs. Tuan Trang, Roger Thompson, and Darren Derksen.
Researchers out of the Hotchkiss Brain Institute at the University of Calgary have discovered a treatment that shows potential in alleviating opioid withdrawal symptoms, which can help break the cycle of opioid use for millions worldwide. Join our leading scientist Dr. Tuan Trang and other scientific, medical and mental health and addictions experts for this community-run webinar with the Hotchkiss Brain Institute discussing the potential of this research, what this means for communities worldwide, and plans to fuel the development of the science from bench to bedside.
Governments across North America are taking urgent action to address the growing opioid crisis that is drastically gaining momentum. Current interventions have proven to be ineffective when trying to manage the growing overdose numbers and the number of patients experiencing debilitating withdrawal symptoms. We have compiled the latest articles on the subject, contextualizing the crisis, and emphasizing the global need for innovative
AphioTx, a clinical research company from the University of Calgary developing a potential treatment for opioid withdrawal, is pleased to announce its formal launch today.
The CIHR Project Grant program chose projects led by Drs. Sabine Gilch, PhD, Tuan Trang, PhD, and Patrick Whelan, PhD, all researchers in the University of Calgary Faculty of Veterinary Medicine (UCVM).
Opioid use and abuse is a significant social, health and economic issue in Canada. Researchers at the University of Calgary’s Faculty of Veterinary Medicine (UCVM) and Hotchkiss Brain Institute (HBI) at the Cumming School of Medicine (CSM) have discovered that an existing anti-gout medication is effective in reducing the severity of withdrawal symptoms in opioid-dependent rodents.
Researchers at the University of Alberta have developed a new method of controlling biology at the cellular level using light.
The opium poppy is a natural source of opioids such as morphine. Although they are revered for their potent pain-relieving effects, when used chronically, opioids can lead to analgesic tolerance, hyperalgesia and withdrawal. Burma et al. (p 355) show that pannexin-1 (Panx1) channels on spinal microglia are essential for opioid withdrawal, and that
Opioids are the mainstay of treatment strategies to reduce pain, but withdrawal can be a serious problem when patients stop taking these drugs. However, beyond the recognition that microglia play a role in this phenomenon, little is known about the cellular mechanisms involved. Now, new research shows how microglia contribute to withdrawal in rodents and identifies a potential path toward easing withdrawal in patients.
Drug eases withdrawal symptoms in rodents, human trials next Originally published by CBC News on January 30, 2017 University of Calgary researchers believe a medication already being used to treat gout could be a weapon in the fight against opioid dependency — by alleviating withdrawal symptoms. “It’s quite effective [on
Originally published by The Globe and Mail on January 30, 2017 Researchers in Alberta have discovered that a medication once used to treat gout is effective in reducing withdrawal symptoms in opioid-dependent rodents, raising the possibility it could one day do the same for humans. The researchers, from the University
The Canadian Association for Neuroscience (CAN) is proud to announce that Tuan Trang, from the Hotchkiss Brain Institute at the University of Calgary, will receive a 2017 CAN Young Investigator Award at the upcoming 11th Annual Canadian Neuroscience Meeting in Montréal, on May 30th 2017.
Tuan Trang (Award in Pain Recipient) began his research career as an undergraduate at Queen’s University studying the effects of prenatal alcohol exposure.
